Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions

Transplantation
M D McKisicA L Smith

Abstract

Lymphocytotropic mouse parvoviruses can perturb immune responses. For example the recently identified mouse parvovirus designated MPV-1 persistently infects lymphoid tissues and interferes with the ability of cloned T cells to proliferate. As a consequence of these findings the present studies were undertaken to characterize further the immunomodulatory effects of MPV-1 on T cell-mediated immune responses in vivo and in vitro. To evaluate the effect of MPV-1 on CD8+ T cell-mediated responses sarcoma I (SaI) cells, devoid of class II major histocompatibility (MHC) antigens, were administered to MPV-1-infected adult BALB/c mice. MPV-1 infection accelerated tumor allograft rejection. Immunofluorescence staining and in situ hybridization studies of tumors suggested that direct infection of the tumor cells was not responsible for accelerated rejection. Furthermore, compared with uninfected mice, T cells from infected mice that had rejected SaI tumors had a diminished cytolytic capacity. Taken together these results suggest that MPV-1 may induce "bystander help." To examine the in vivo effect of MPV-1 on CD4+ T cell mediated responses adult mice were primed with ovalbumin (OVA) and infected with MPV-1. Spleen and popliteal lymph node...Continue Reading

References

Jan 1, 1992·Annual Review of Immunology·P C DohertyS R Carding
Aug 1, 1991·Journal of Virological Methods·J Rommelaere, J J Cornelis
Feb 24, 1989·Cell·M B Oldstone
Apr 10, 1986·Nature·P T MassaV ter Meulen
Jan 1, 1987·Advances in Virus Research·S F Cotmore, P Tattersall
Jul 1, 1986·Journal of Virology·P B KimseyC V Jongeneel
Dec 1, 1974·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·I W McLean, P K Nakane
Aug 1, 1966·Virology·L V Crawford
Jan 1, 1981·Immunological Reviews·A L GlasebrookF W Fitch
Apr 1, 1980·The Journal of Experimental Medicine·A L Glasebrook, F W Fitch
Jun 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·J KapplerP Marrack
Jun 1, 1995·Journal of Virology·R O JacobyM D McKisic
Oct 1, 1994·Journal of Virology·L J Ball-Goodrich, E Johnson
Jan 28, 1994·Cell·P Marrack, J Kappler

❮ Previous
Next ❯

Citations

Mar 28, 1998·Breast Cancer Research and Treatment·S P Schiffer
May 1, 2003·Lab Animal·Robert S Livingston, Lela K Riley
Jan 19, 2008·Cancer Gene Therapy·L KrügerJ A Kleinschmidt
May 29, 2008·ILAR Journal·David G BesselsenLela K Riley
Sep 5, 2002·Journal of Virology·Lisa J Ball-GoodrichRobert O Jacoby
Apr 3, 2013·Experimental and Molecular Pathology·Joongho JohShin-Je Ghim
Jul 23, 2014·Lab Animal·Jori LeszczynskiCarolyn Russell
Mar 27, 2007·Cancer Letters·Markus J V Vähä-KoskelaAri E Hinkkanen
Dec 17, 2011·Veterinary Pathology·P M TreutingC F Brayton
Nov 1, 2011·Laboratory Animals·Lydia M Janus, Andre Bleich
Feb 24, 2001·Veterinary Pathology·C BraytonC A Montgomery
Jan 4, 2018·Lab Animal·Caroline J Zeiss, Cory F Brayton
May 8, 2019·Viruses·Assia Angelova, Jean Rommelaere
May 13, 2006·The Journal of General Virology·David G BesselsenRobert S Livingston
Apr 3, 1998·Journal of Virology·L J Ball-GoodrichR O Jacoby
Jun 3, 2021·Animals : an Open Access Journal From MDPI·Stephanie Buchheister, André Bleich

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.